12:00 AM
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Enbrel etanercept: Phase III data; marketed

In IMNX’s ongoing 3-year Phase III study of Enbrel in patients with juvenile RA, 80 percent of patients who demonstrated an initial clinical response to treatment continued to respond...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >